| 1. |
|
|
| 2. |
|
|
| 3. |
- Kesteloot, N., et al.
(författare)
-
Deformation and mixing of coexisting shapes in neutron-deficient polonium isotopes
- 2015
-
Ingår i: Physical Review C (Nuclear Physics). - 0556-2813. ; 92:5
-
Tidskriftsartikel (refereegranskat)abstract
- Coulomb-excitation experiments are performed with postaccelerated beams of neutron-deficient Po-196,Po-198,Po-200,Po-202 isotopes at the REX-ISOLDE facility. A set of matrix elements, coupling the low-lying states in these isotopes, is extracted. In the two heaviest isotopes, Po-196,Po-198, the transitional and diagonal matrix elements of the 2(1)(+) state are determined. In Po-196,Po-198 multistep Coulomb excitation is observed, populating the 4(1)(+), 0(2)(+), and 2(2)(+) states. The experimental results are compared to the results from the measurement of mean-square charge radii in polonium isotopes, confirming the onset of deformation from Po-196 onwards. Three model descriptions are used to compare to the data. Calculations with the beyond-mean-field model, the interacting boson model, and the general Bohr Hamiltonian model show partial agreement with the experimental data. Finally, calculations with a phenomenological two-level mixing model hint at the mixing of a spherical structure with a weakly deformed rotational structure.
|
|
| 4. |
- Deisenhammer, F, et al.
(författare)
-
Prediction of natalizumab anti-drug antibodies persistency
- 2019
-
Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 25:3, s. 392-398
-
Tidskriftsartikel (refereegranskat)abstract
- Anti-drug antibodies (ADA) against natalizumab develop early during treatment. ADA persistency is defined by two consecutive positive results as performed by the current qualitative ELISA assay (positive/negative). Very little is known about the magnitude of the natalizumab ADA response and persistency. Design/methods: We developed a highly sensitive natalizumab ADA titration assay on the Meso Scale Discovery (MSD) platform and a pharmacokinetic (PK) assay. We included 43 patients with a positive ELISA-ADA result within 6 months of treatment initiation (baseline) of whom a follow-up serum sample was available 12–30 months after treatment start. MSD-ADA titres and drug levels were measured. Results: Median MSD-ADA titre at baseline was 4881 and 303 at follow-up. A titre of >400 at baseline had a 94% sensitivity and 89% specificity to predict ADA persistency. Reversion to ADA negativity occurred in 10 patients with mean drug levels of 10.8 μg/mL. The median trough drug level in ADA-positive samples was 0 µg/mL. PK levels and ADA titres correlated strongly negatively ( r = −0.67). Conclusion: High baseline natalizumab ADA titres accurately predict persistency. Despite continuous treatment, the majority of patients with persistent ADA had no detectable drug levels indicating loss of efficacy in line with phase 3 study results.
|
|
| 5. |
|
|
| 6. |
- Taheri, M., et al.
(författare)
-
DeepAxe : A Framework for Exploration of Approximation and Reliability Trade-offs in DNN Accelerators
- 2023
-
Ingår i: Proceedings - International Symposium on Quality Electronic Design, ISQED. - : IEEE Computer Society. - 9798350334753
-
Konferensbidrag (refereegranskat)abstract
- While the role of Deep Neural Networks (DNNs) in a wide range of safety-critical applications is expanding, emerging DNNs experience massive growth in terms of computation power. It raises the necessity of improving the reliability of DNN accelerators yet reducing the computational burden on the hardware platforms, i.e. reducing the energy consumption and execution time as well as increasing the efficiency of DNN accelerators. Therefore, the trade-off between hardware performance, i.e. area, power and delay, and the reliability of the DNN accelerator implementation becomes critical and requires tools for analysis.In this paper, we propose a framework DeepAxe for design space exploration for FPGA-based implementation of DNNs by considering the trilateral impact of applying functional approximation on accuracy, reliability and hardware performance. The framework enables selective approximation of reliability-critical DNNs, providing a set of Pareto-optimal DNN implementation design space points for the target resource utilization requirements. The design flow starts with a pre-trained network in Keras, uses an innovative high-level synthesis environment DeepHLS and results in a set of Pareto-optimal design space points as a guide for the designer. The framework is demonstrated on a case study of custom and state-of-the-art DNNs and datasets.
|
|
| 7. |
- Wallin, Anders, 1950, et al.
(författare)
-
Donepezil in Alzheimer's disease : What to expect after 3 years of treatment in a routine clinical setting
- 2007
-
Ingår i: Dementia and Geriatric Cognitive Disorders. - Basel : S. Karger AG. - 1420-8008 .- 1421-9824. ; 23:3, s. 150-160
-
Tidskriftsartikel (refereegranskat)abstract
- Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points, 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting. Copyright © 2007 S. Karger AG.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
